IQuity is a Nashville, Tenn.-based life science tech company that leverages machine learning methods to deliver RNA analytics for autoimmune disease. The company is developing RNA-based diagnostic tests, including IsolateMS, its first test to detect multiple sclerosis. IQuity says its assays measure RNA in patient blood samples to detect the presence or absence of several autoimmune diseases. The company raised $2.35M in funding and intends to use the proceeds to open a new CLIA-certified laboratory in Nashville. Backers were not disclosed in the report. IQuity plans to begin taking orders from physicians in late May for IsolateMS; Chase Spurlock is founder and CEO. IQuity Labs builds leading‑edge diagnostic test panels that confirm the presence or absence of autoimmune disease using a minimally invasive blood draw. The company’s core test technology was developed within Vanderbilt University Medical Center’s research community and has received peer‑reviewed grant funding from the National Institutes of Health. IQuity plans to launch its first test for multiple sclerosis in the second quarter of 2016, with additional autoimmune disease panels rolling out throughout the second half of 2016. In the second half of 2016 the company also plans to introduce tests under development in gastroenterology and rheumatology. The tests are intended to help providers diagnose patients sooner, improve outcomes, and reduce costs associated with misdiagnosis or delayed intervention. The company is positioning its products to address a large market: the article cites an NIH estimate that autoimmune disease costs $100 billion per year and affects one in 20 Americans.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

May 2017